Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G.
Marie V NelsonAe Rang KimP Mickey WilliamsSinchita Roy-ChowdhuriDavid R PattonBrent D CoffeyJoel M ReidJin PiaoLauren SaguiligTodd A AlonzoStacey L BergNilsa C RamirezAlok JajuElizabeth FoxBrenda J WeigelDouglas S HawkinsMargaret M MooneyNaoko TakebeJames V TricoliKatherine A JanewayNita L SeibelD Williams ParsonsPublished in: The oncologist (2024)
There was a low accrual rate on this MATCH subprotocol, with only 18% of those who matched with BRAFV600 mutations enrolling, resulting in early termination, and limiting study results (ClinicalTrials.gov Identifier: NCT03220035).